Schläpfer Jürg, Rapp Fabrice, Kappenberger Lukas, Fromer Martin
Division of Cardiology, University Hospital (CHUV), 1011 Lausanne, Switzerland.
J Am Coll Cardiol. 2002 Jun 5;39(11):1813-9. doi: 10.1016/s0735-1097(02)01863-6.
We sought to compare the long-term survival rates of patients with sustained ventricular tachyarrhythmia after myocardial infarction (MI) who were treated according to the results of electrophysiological (EP) study either with amiodarone or an implantable cardioverter-defibrillator (ICD).
Patients with sustained ventricular tachyarrhythmias after MI are at high risk of sudden cardiac death (SCD). However, data comparing the long-term survival rates of patients treated with amiodarone or ICD, according to the results of EP testing, are lacking.
Patients underwent a first EP study at baseline and a second one after a loading dose of amiodarone of 14 +/- 2.9 g. According to the results of the second EP study, patients were classified either as responders or non-responders to amiodarone; non-responders were eventually treated with an ICD.
Eighty-four consecutive patients with MI (78 men; 21-77 years old; mean left ventricular (LV) ejection fraction 36 +/- 11%) were consecutively included. Forty-three patients (51%) were responders, and 41 patients (49%) were non-responders to amiodarone therapy. During a mean follow-up period of 63 +/- 30 months, SCD and total mortality rates were significantly higher in the amiodarone-treated patients (p = 0.03 and 0.02, respectively).
The long-term survival of patients with sustained ventricular tachyarrhythmias after MI, with depressed LV function, is significantly better with an ICD than with amiodarone therapy, even when stratified according to the results of the EP study. These patients should benefit from early ICD placement, and any previous amiodarone treatment seems to have no additional value.
我们试图比较心肌梗死(MI)后持续性室性心律失常患者,根据电生理(EP)研究结果,接受胺碘酮或植入式心脏复律除颤器(ICD)治疗后的长期生存率。
MI后持续性室性心律失常患者发生心源性猝死(SCD)的风险很高。然而,根据EP测试结果比较接受胺碘酮或ICD治疗患者的长期生存率的数据尚缺乏。
患者在基线时进行首次EP研究,并在给予14±2.9g胺碘酮负荷剂量后进行第二次研究。根据第二次EP研究结果,患者被分为胺碘酮反应者或无反应者;无反应者最终接受ICD治疗。
连续纳入84例MI患者(78例男性;21 - 77岁;平均左心室(LV)射血分数36±11%)。43例患者(51%)为胺碘酮反应者,41例患者(49%)为胺碘酮无反应者。在平均63±30个月的随访期内,胺碘酮治疗组患者的SCD和总死亡率显著更高(分别为p = 0.03和0.02)。
MI后伴有LV功能降低的持续性室性心律失常患者,即使根据EP研究结果进行分层,ICD治疗的长期生存率也显著优于胺碘酮治疗。这些患者应从早期ICD植入中获益,且之前的任何胺碘酮治疗似乎并无额外价值。